
TSE:MFC
This summary was created by AI, based on 28 opinions in the last 12 months.
Manulife Financial (MFC) has garnered mixed reviews from experts, reflecting a range of perspectives on its current standing and future potential. Several analysts highlight the company's strong dividend yield and its robust performance in Asia, suggesting it may be a worthwhile long-term investment, particularly for those seeking income rather than growth. However, concerns regarding earnings fluctuations, market pullbacks, and comparisons with peers like Sun Life Financial indicate that MFC may not be as attractive as other options in the life insurance sector. Many experts recognize the potential for capital appreciation, yet they caution that the stock faces headwinds, especially when considering broader market dynamics and the performance of similar financial institutions. There is a prevailing sentiment that the stock remains a reliable choice, albeit needing careful monitoring amidst potential market corrections.
Lifecos? He owns Sun Life (SLF-T) and Manulife (MFC-T). The problem with life insurance companies, especially when interest rates are getting so low and negative, how do you fund long-term liability? That has been a conundrum. When there started to be a turn in interest rates, suddenly lifecos became more interesting investments, and he added to his holdings. Because of the big move, he has taken a bit of money out recently. He likes their growth, but valuations are at the higher end and expectations of higher interest rates are a little too bullish. He would recommend that you take some profits like he did.
All insurance companies do better in a rising interest rate environment. They also do very much better if they are selling equity type products, which they all do. Any increase in North American equity markets is good for the companies. He feels this company has too much of their future growth tied up in Asia, and he doesn’t trust the Asian markets. (See Top Picks.)
Ran into serious problems during the financial crisis and had to cut the dividend in half. They had to restructure, not only their balance sheet, but also their product line. They’ve made huge inroads expanding geographically. Although it has appreciated recently, it is a company that will appreciate very well in a rising interest rate environment. Has a very strong operations in the US. Their sales in Asia have been doing extremely well. Believes we are going to be seeing more dividend increases, probably in the near term. Dividend Yield of 2.96%. (Analysts’ price target is $26.61.)
He likes the look of this. Insurance companies have all had a big move post election, on the premise that we are going to see increased rates. They’ll be big benefactors of that. A dividend increase is a very likely possibility. It’ll be modest and not likely as large a magnitude as the past 3 years. Valuations are very reasonable. Dividend yield is 3%, which is certainly adequate to hold in this environment. This and Sun Life (SLF-T) have the biggest exposure to international markets, which is going to be a key to them.
This is really growing well in Asia. He models a 12% EPS. Last quarter was a beat. 9% dividend growth. Still trading below its peers. Trading at 13.1X 2016, which isn’t bad relative to the TSX. Very strong balance sheet. They benefit from really good FX tailwinds to the Cdn$. They’ve taken some recent actuarial charges against their long-term care unit, which should make their quarters quieter going forward. This is an interest rate play, so as interest rates start to go higher, they should benefit. Dividend yield of 3.04%. (Analysts’ price target is $25.83.)
The 35-year run in the bond market is drawing to a close. All insurers are very heavily exposed on their balance sheets and through their general funds to fixed income securities. Whether mortgages, publicly traded bonds, private loans, etc. They’ve managed to claw and scratch and make money in a very repressive interest rate environment for many years. With rates backing up, it should be a tremendous boon to profitability. Trading at 1.25X BV so it is not expensive. Dividend yield of 2.97%. (Analysts’ price target is $24.92.)
This looks like it has decent earnings growth into 2017 off of 2016. It has had a big run with the Trump rally, but remember all these life insurance companies fare a lot better in a rate environment where rates aren’t at zero and the curve isn’t flat. It should continue to do better here. There is nothing wrong with this company.
He was adding to his positions at the $17 level. Now the question is, how fast do interest rates rise, how far do the rise, and how much does it help them. On their most recent quarter, their core earnings beat estimates and were better than expected, but their headline earnings were $.01, because they lost a lot of money on hedging and interest rates. That is short term. He likes this for the long-term, but would be looking for a better entry point in the low $20s. 3.3% dividend yield.